High dose calcitriol may reduce thrombosis in cancer patients
نویسندگان
چکیده
منابع مشابه
Risk Factors of Deep Vein Thrombosis in Cancer Patients
Background: Venous thromboembolism (VTE) is a significant complication in cancer patients which was found in 4-20% of the patients. This study was aimed to evaluate risk factors of deep vein thrombosis (DVT) in cancer patients in an oncology center in Indonesia. Methods: This was a retrospective cohort study. Data were obtained from medical records of adult cancer patients with DVT referring ...
متن کاملAromatase inhibitors may reduce endometrial cancer risk.
Use of aromatase inhibitors, which are known to reduce endogenous oestrogen levels, as adjuvant therapy had a lower risk of endometrial cancer, compared with that of patients who were treated with tamoxifen, results of a new study show. In this study, Rowan Chleblowski and colleagues (Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, CA, USA) examined the rec...
متن کاملA thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children.
Important predictors of adverse outcomes of thrombosis in children, including postthrombotic syndrome (PTS), have recently been identified. Given this knowledge and the encouraging preliminary pediatric experience with systemic thrombolysis, we sought to retrospectively analyze our institutional experience with a thrombolytic regimen versus standard anticoagulation for acute, occlusive deep ven...
متن کاملPhase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.
BACKGROUND Data suggest that vitamin D plays a role in the treatment and prevention of prostate cancer. The combination of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) plus dexamethasone was studied based on evidence that dexamethasone potentiates the antitumor effects of calcitriol and ameliorates hypercalcemia. METHODS Oral calcitriol was administered weekly, Monday, Tuesda...
متن کاملA Phase I Study of High-Dose Calcitriol in Combination with Temozolomide for Patients with Metastatic Melanoma
BACKGROUND Temozolomide is efficacious as an oral alternative for patients with metastatic melanoma (MM). Calcitriol has anti-proliferative properties and vitamin D receptor (VDR) polymorphisms are associated with alterations in melanoma susceptibility and progression. METHODS Tem 150 mg/m2 was administered on days 2-8 and 16-22 every 28 days. Calcitriol was given on days 1 and 15 every 28 da...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 2006
ISSN: 0007-1048,1365-2141
DOI: 10.1111/j.1365-2141.2006.06322.x